Key facts
- This page summarizes Razi Ingber's Form 3 filing for RedHill Biopharma Ltd. (RDHL).
- 0 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 18 Mar 2026, 13:10.
Razi Ingber - 18 Mar 2026 Form 3 Insider Report for RedHill Biopharma Ltd. (RDHL)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- RDHL
- Reported as of
- 18 Mar 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Razi Ingber
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Razi Ingber filed Form 3 for RedHill Biopharma Ltd. (RDHL) on 18 Mar 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002113213
Primary reporting owner
Ingber Razi
- Relationship
- Chief Financial Officer
- Address
- 21 HA'ARBA'A STREET, TEL AVIV, ISRAEL
- Signature
- /s/ Razi Ingber
- Signature date
- 18 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RDHL
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 277,560,000
- Date
- 18 Mar 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RDHL
holding
Derivative
American Depositary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 66,910,000
- Exercise price
- Footnotes
- F2
RDHL
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 20,000
- Exercise price
- Footnotes
- F3
RDHL
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 30,000
- Exercise price
- Footnotes
- F4
RDHL
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 170,000
- Exercise price
- Footnotes
- F5
RDHL
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 230,000
- Exercise price
- Footnotes
- F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
Represents 27,756 unvested restricted share units ("RSUs"), each with respect to one American Depositary Share ("ADS"), which represents 10,000 ordinary shares, par value NIS 0.01 per share ("Ordinary Shares"), of RedHill Biopharma Inc. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares.
Footnote F2
Represents 6,691 ADSs, which are convertible at any time, at the holder's election and have no expiration date.
Footnote F3
Represents stock option to purchase 20,000 Ordinary Shares (equivalent to 2 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $5,000 per ADS and the option expires on August 29, 2028.
Footnote F4
Represents stock option to purchase 30,000 Ordinary Shares (equivalent to 3 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $5,000 per ADS and the option expires on May 6, 2029.
Footnote F5
Represents stock option to purchase 170,000 Ordinary Shares (equivalent to 17 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $7,720 per ADS and the option expires on June 30, 2030.
Footnote F6
Represents stock option to purchase 230,000 Ordinary Shares (equivalent to 23 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $7,080 per ADS and the option expires on April 28, 2031.